EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Non- Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia , and Acinetobacter baumannii

Andrew J Fratoni iD, Matthew L Gethers, David P Nicolau, Joseph L Kuti

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf403 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Andrew J Fratoni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, beta-Lactamases, Acinetobacter baumannii, Stenotrophomonas maltophilia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: Center for Anti-Infective Research and Development, Hartford Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The β-lactam/β-lactamase inhibitor (BL/BLI) combination drugs, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/relebactam, have proven especially useful for treating carbapenemase-producing, carbapenem-resistant organisms (CRO), specifically Klebsiella pneumoniae carbapenemases (KPCs). However, non-KPC mechanisms of resistance are rising in prevalence among Gram-negatives and are increasingly challenging to treat. These newer BL/BLIs, including sulbactam/durlobactam, have an array of activity against mechanisms of carbapenem resistance beyond KPC and therefore play an important role in the treatment of non-KPC carbapenem-resistant organisms. This review, the second in a 2-part series, lays out the non-KPC attributes of the newer BL/BLIs with a focus on clinical utility against Burkholderia cepacia complex, Stenotrophomonas maltophilia, Acinetobacter baumannii, and other rare pathogens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-Lactamase Inhibitorsbeta-LactamasesAcinetobacter baumanniiStenotrophomonas maltophiliaBacterial ProteinsAnti-Bacterial AgentsBurkholderia cepacia complexHumansGram-Negative Bacterial Infections

Stichwörter der Autor:innen

aztreonamceftazidime/avibactamimipenem/relebactammeropenem/vaborbactamsulbactam/durlobactam

Substanzen

beta-Lactamase Inhibitorsbeta-LactamasescarbapenemaseBacterial ProteinsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA.
  • Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA.

ORCID-Profile: Andrew J Fratoni

Förderung

  • Center for Anti-Infective Research and Development
  • Hartford Hospital

Zitieren

APA

Fratoni, A. J., Gethers, M. L., Nicolau, D. P., & Kuti, J. L. (2025). Non- Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia , and Acinetobacter baumannii. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf403

Vancouver

Fratoni AJ, Gethers ML, Nicolau DP, Kuti JL. Non- Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia , and Acinetobacter baumannii. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf403

BibTeX
@article{Fratoni2025,
  author = {Fratoni, Andrew J and Gethers, Matthew L and Nicolau, David P and Kuti, Joseph L},
  title = {Non- Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia , and Acinetobacter baumannii},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf403}
}
Kostenlos starten →